Cellectar Biosciences INC NEW closed at $1.23 on Nov 4, down 6.11%, 69.6% below its 52-week closing high. Volume of 87.8K shares was 0.50× its 20-day average (below normal).
Split-adjusted performance: -18.5% over one month, -65.2% over six months, -62.7% over one year.
Short interest was 263.5K shares at the Oct 15 settlement, up 58.5% from the prior report (2.9% of float, 1.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| CLRBCellectar Biosciences INC NEW | $1.23 | −6.11% | −65.2% | — | — | — | $11.6M | |
| BIVIBioVie | $1.34 | −22.54% | −19.3% | — | — | — | $11.6M | Compare |
| TVRDTvardi Therapeutics | $0.8614 | +3.17% | −76.5% | — | — | — | $11.5M | Compare |
| LSTALisata Therapeutics | $1.06 | −2.75% | −67.5% | −100.0% | — | — | $11.5M | Compare |
| LPCNLipocine | $1.44 | −1.37% | −40.7% | −100.0% | — | — | $11.9M | Compare |
| HINDVyome Holdings | $1.74 | −1.93% | −21.1% | — | −2543.3% | — | $12.2M | Compare |
| RKTORocket One | $0.4422 | −4.33% | — | — | — | — | $11.0M | Compare |
| AEONAEON Biopharma | $0.2086 | −1.70% | −77.0% | — | — | — | $12.3M | Compare |
| PTNPalatin Technologies | $6.02 | +15.33% | −68.3% | — | −1449.1% | — | $10.7M | Compare |
No recent articles focused on Cellectar Biosciences INC NEW.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
